- Home
- / Tiburio Therapeutics
Tiburio Therapeutics
Total Funding
$31 M
Tiburio Therapeutics Summary
Company Summary
- Overview
- Tiburio Therapeutics is a biopharmaceutical company, which is dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases. The Company's pipeline consists of two clinical stage compounds: TBR-760 for the treatment of non-functioning pituitary adenoma, and TBR-065 for additional rare endocrine diseases.
- Type
- Private
- Status
- Active
- Founded
- 2018
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.tiburio.com
- Cybersecurity rating
Table of Contents
Key People
Sandip K. Agarwala, Director
Michael D. Culler, Scientific Founder and Chairman, Scientific Advisory Board
Mette Kirstine Agger, Director
LocationsView all
1 location detected
Cambridge, MA HQ
United States
NE48, 700 Technology Square 2nd Floor